RNAZ News and Press, TransCode Therapeutics Inc. From 12/12/23

BOSTON, Dec. 12, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported successful completion of a preclinical study comprising four independent replicates with its lead th...

BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, will present data from a Phase 0 clinical trial with its lead candidate, TTX-MC138, at this year’s San Anton...

BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has closed its previously announced registered direct offering...

2023-12-01 06:56:23 ET More on TransCode Therapeutics TransCode shares plunge 20% on stock offering, Nasdaq compliance update TransCode Therapeutics announces public offering of common stock Seeking Alpha’s Quant Rating on TransCode Therapeutics H...

BOSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement fo...

BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2023, and recent business progress. ...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

TransCode Therapeutics Inc. (RNAZ) is expected to report $-1.5 for Q3 2023

2023-10-31 09:34:15 ET A Boston-based %Biotech that is no stranger to capturing our attention is at it again on Tuesday morning after the company announced that it is withdrawing the underwritten public offering of its common stock. According to the release, “this reflects the Co...

2023-10-30 16:42:47 ET More on TransCode Therapeutics TransCode shares plunge 20% on stock offering, Nasdaq compliance update TransCode Therapeutics announces public offering of common stock Historical earnings data for TransCode Therapeutics For further...